Trial
NCT04624113
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Epizyme, Inc.
Condition
Head and Neck Squamous Cell Carcinoma
Intervention
Tazemetostat
Why stopped
Ipsen bought out Epizyme
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-21